We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04454463
Recruitment Status : Recruiting
First Posted : July 1, 2020
Last Update Posted : February 9, 2023
Sponsor:
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Baylor College of Medicine
Case Western Reserve University
Duke University
Ann & Robert H Lurie Children's Hospital of Chicago
Indiana University
Liver Institute Northwest
Seattle Children's Hospital
St. Louis University
University of California, San Diego
University of California, San Francisco
University of Southern California
Virginia Commonwealth University
Emory University
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Johns Hopkins Bloomberg School of Public Health

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.

Condition or disease
Liver Diseases

Detailed Description:
This is a multicenter, prospective follow-up study of patients with known nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). The primary objective of the study is to investigate the etiology, pathogenesis, natural history, diagnosis, treatment, and prevention of NAFLD and NASH.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2250 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Actual Study Start Date : November 13, 2020
Estimated Primary Completion Date : June 30, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Adult patients with NAFLD
1500 patients 18 years and older at the time of enrollment.
Pediatric patients with NAFLD
750 patients 2 years or older and up to 17 years old at the time of enrollment.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in alanine aminotransferase (ALT) levels from baseline to one year. [ Time Frame: Baseline and 1 year ]
    ALT measure in IU/L (higher ALT indicates worse outcomes)


Biospecimen Retention:   Samples With DNA
plasma, serum, liver tissue

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The study population will be at least 2250 patients age 2 years or older with histologically confirmed NAFLD or NASH located in the United States:

  • 1500 patients 18 years and older at the time of enrollment.
  • 750 patients 2 years or older and up to 17 years old at the time of enrollment.
Criteria

Inclusion Criteria:

  • 2 years of age or older as of the initial screening interview and provision of consent
  • Willingness to participate in the study for 1 or more years
  • Histologic evidence of NAFLD or NASH based upon a standard of care liver biopsy
  • Collection of serum and plasma up to 90 days before or 4- 90 days after standard of care liver biopsy
  • Absence of regular or excessive use of alcohol within 2 years prior to initial screening

Exclusion Criteria:

  • Clinical or histological evidence of alcoholic liver disease: Regular and excessive use of alcohol within the 2 years prior to interview defined as alcohol intake greater than 14 drinks per week in a man or greater than 7 drinks per week in a woman. Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 1 ounce of distilled spirits, one 12-oz beer, or one 4-oz glass of wine
  • Total parenteral nutrition for more than 1 month within a 6-month period before baseline liver biopsy
  • Short bowel syndrome
  • History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric surgery performed following enrollment is not exclusionary. Liver biopsies obtained during bariatric surgery cannot be used for enrollment because of the associated surgical or anesthetic acute changes and the weight loss efforts that precede bariatric surgery
  • History of biliopancreatic diversion
  • Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score equal to or greater than 10
  • Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (patients with isolated antibody to hepatitis B core antigen, anti-HBc total, are not excluded)
  • Evidence of chronic hepatitis C as marked by the presence of anti-HCV or HCV RNA in serum
  • Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of the investigator)
  • Wilson's disease
  • Known glycogen storage disease
  • Known dysbetalipoproteinemia
  • Known phenotypic hemochromatosis (HII greater than 1.9 or removal of more than 4 g of iron by phlebotomy)
  • Prominent bile duct injury (florid duct lesions or periductal sclerosis) or bile duct paucity
  • Chronic cholestasis
  • Vascular lesions (vasculitis, cardiac sclerosis, acute or chronic Budd-Chiari, hepatoportal sclerosis, peliosis)
  • Iron overload greater than 3+
  • Zones of confluent necrosis, infarction, massive or sub-massive, pan-acinar necrosis
  • Multiple epithelioid granulomas
  • Congenital hepatic fibrosis
  • Polycystic liver disease
  • Other metabolic or congenital liver disease
  • Evidence of systemic infectious disease
  • Known HIV positive
  • Disseminated or advanced malignancy
  • Concomitant severe underlying systemic illness that in the opinion of the investigator would interfere with completion of follow-up
  • Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of study
  • Inability to complete the appropriate informed consent process
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04454463


Contacts
Layout table for location contacts
Contact: Peggy Adamo, MS 410-502-9137 madamo1@jhu.edu
Contact: Emily Mitchell, MPH 410-955-8183 esharke5@jhu.edu

Locations
Layout table for location information
United States, California
University of California, San Diego- Adults Recruiting
La Jolla, California, United States, 92103
Contact: Egbert Madamba    858-246-2227    emadamba@health.ucsd.edu   
Contact: Lisa Richards    (858) 246-2254    lrichards@health.ucsd.edu   
Principal Investigator: Rohit Loomba, MD         
University of Southern California Recruiting
Los Angeles, California, United States, 90089
Contact: Daisy Olvera    323-442-0535    daisy.olvera@med.usc.edu   
Principal Investigator: Norah Terrault, MD, MPH         
University of California, San Diego Pediatrics Recruiting
San Diego, California, United States, 92103
Contact: Paty Ugalde-Nicalo    619-543-7673    pugaldenicalo@ucsd.edu   
Principal Investigator: Jeffrey Schwimmer, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Rae Davis    415-514-3274    rayshawnda.davis@ucsf.edu   
Contact: Remi Awe    (415) 502-2906    remilekun.awe@ucsf.edu   
Principal Investigator: Norah Terrault, MD         
Sub-Investigator: Bilal Hameed, MD         
United States, Georgia
Emory University-Pediatrics Recruiting
Atlanta, Georgia, United States, 30322
Contact: Carmen Garcia    404-727-9876    cgarc40@emory.edu   
Principal Investigator: Miriam Vos, MD, PhD         
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago Recruiting
Chicago, Illinois, United States, 60614
Contact: Mary Riordan    312-227-4558    mriordan@luriechildrens.org   
Contact: Angela Anthony    (312) 227-4559    aanthony@luriechildrens.org   
Principal Investigator: Mark Fishbein, MD         
United States, Indiana
Indiana University- Adults Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Lisa Garrison    317-278-3206    ljgarris@iu.edu   
Contact: Mandy Cruz    (317) 278-6210    mandcruz@iu.edu   
Principal Investigator: Naga Chalasani, MD         
Riley Hospital for Children Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Wendy Morlan    317-274-9601    wmorlan@iu.edu   
Contact: Kelley Jackson    317-974-9671    ksj4@iu.edu   
Principal Investigator: Jean Molleston, MD         
United States, Missouri
St. Louis University Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Theresa Cattoor, RN    314-977-9355    theresa.cattooor@health.slu.edu   
Contact: Shirley Campbell    (314) 977-9336    shirley.campbell@health.slu.edu   
Principal Investigator: Brent Tetri, MD         
Sub-Investigator: Ajay Jain, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Mariko Kopping    919-684-4798    mariko.kopping@duke.edu   
Contact: Naglaa Tawadrous    (919) 668-5819    naglaa.tawadrous@duke.edu   
Principal Investigator: Anna Mae Diehl, MD         
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229-3039
Contact: Ann Popelar    516-636-8867    ann.popelar@cchmc.org   
Principal Investigator: Stavra Xanthakos, MD         
Sub-Investigator: Marialena Mouzaki, MD         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Rahul Yerrapothu    216-445-4863    yerrapr@ccf.org   
Contact: Annette Bellar    (216) 636-5247    bellara@ccf.org   
Principal Investigator: Srinivasan Dasarathy, MD         
United States, Texas
Texas Children's Hospital, Baylor University Recruiting
Houston, Texas, United States, 77030
Contact: Cynthia Tsai    832-822-3634    ct2@bcm.edu   
Contact: Donna Garner    832-822-4009    dkgarner@bcm.edu   
Principal Investigator: Paula Hertel, MD         
United States, Virginia
Virginia Commonwealth University Recruiting
Richmond, Virginia, United States, 23298
Contact: Sherry Boyett    804-828-5434    sherry.boyett@vcuhealth.org   
Contact: Jolene Schlosser    (804) 828-9195    jolene.schlosser@vcuhealth.org   
Principal Investigator: Arun J Sanyal, MD         
United States, Washington
Liver Institute Northwest Recruiting
Seattle, Washington, United States, 98105
Contact: Theresa Dorrian    206-536-3030    tdorrian@liverinstitutenw.org   
Contact: Pannapat Angkanaworakul    (206) 536-3030    pannapat@liverinstitutenw.org   
Principal Investigator: Kris Kowdley, MD         
Seattle Children's Hospital- SEA Recruiting
Seattle, Washington, United States, 98105
Contact: Melissa Young    206-987-1037    melissa.young@seattlechildrens.org   
Principal Investigator: Niviann Blondet, MD         
Sponsors and Collaborators
Johns Hopkins Bloomberg School of Public Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Baylor College of Medicine
Case Western Reserve University
Duke University
Ann & Robert H Lurie Children's Hospital of Chicago
Indiana University
Liver Institute Northwest
Seattle Children's Hospital
St. Louis University
University of California, San Diego
University of California, San Francisco
University of Southern California
Virginia Commonwealth University
Emory University
Children's Hospital Medical Center, Cincinnati
Investigators
Layout table for investigator information
Principal Investigator: Arun Sanyal, MD Virginia Commonwealth University Medical Center
Principal Investigator: Brent Tetri, MD St Louis University Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier: NCT04454463    
Other Study ID Numbers: NAFLD Database 3
U01DK061732 ( U.S. NIH Grant/Contract )
U01DK061713 ( U.S. NIH Grant/Contract )
U01DK061737 ( U.S. NIH Grant/Contract )
U01DK061718 ( U.S. NIH Grant/Contract )
U01DK061734 ( U.S. NIH Grant/Contract )
U01DK061738 ( U.S. NIH Grant/Contract )
U01DK061728 ( U.S. NIH Grant/Contract )
U01DK061731 ( U.S. NIH Grant/Contract )
U24DK061730 ( U.S. NIH Grant/Contract )
First Posted: July 1, 2020    Key Record Dates
Last Update Posted: February 9, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The NASH CRN is fully committed to resource sharing beyond the NASH CRN investigators. The NASH CRN will make deposits to the NIDDK Central Data Repository according to the requirements outlined in the NIDDK Data Sharing Policy published in July 2013.
Supporting Materials: Study Protocol
Informed Consent Form (ICF)
Analytic Code
Time Frame: Within two years of end of the funding cycle.
Access Criteria: All qualified investigators will be allowed access to the stored materials at the end of a pre-determined proprietary period.
URL: https://repository.niddk.nih.gov/home/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Johns Hopkins Bloomberg School of Public Health:
NAFLD
NASH
non-alcoholic steatohepatitis
fatty liver disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases